IL-15SAPBSCBD IL-15SA
… conducted on mice bearing CT26 tumours treated with PBS (n=5), IL-15SA (n=8) or equimolar CBD IL-15SA (n=8) and sacrificed 24 hours af…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 481–540 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
SGLT2 inhibitors7Tebentafusp7ethambutol7Albumin7mSTAR13027Bimekizumab7LA7RPV7Alirocumab7Ixekizumab7TXA7pyrazinamide7Antidepressant7B7-H37Botox7Ibrutinib7Apalutamide7Heroin7MRA7Palbociclib7TGF-β17bDMARD7Enfortumab vedotin7fluoroquinolones7sintilimab7DES7IL-107Neostigmine7bDMARDs7methamphetamine7posaconazole7MDMA7Tetracycline7Labetalol7Piperacillin-tazobactam7Acyclovir7DOACs7IL-67Monoclonal antibodies7NSAID7TGF-β7DORAvirine7Nimodipine7bronchodilator7leflunomide7melphalan7metoprolol70.2% ropivacaine7Antihypertensives7NSAIDs7angiotensin receptor blockers7anticentromere7bortezomib7clindamycin7codeine7dipeptidyl peptidase-4 inhibitors7esomeprazole7flucloxacillin7Glucagon-like peptide-1 (GLP-1) receptor agonists7Janus kinase inhibitors7
Articles mentioning drugs
10,506 articles · page 10 of 876metforminbasal insulinGLP-1 RASGLT-2
…pants taking two medications, the most common combinations were metformin with a sulfonylurea (n=31 (27%) in the CGM group and n=21 (36%)…
methylcobalamin
…Abstract Objective To evaluate whether methylcobalamin could effectively and safely prevent hand-foot syndrome in pati…
DexamethasoneDXMdexmedetomidine
…verse effectsReferences Pehora C, Pearson AM, Kaushal A, et al. Dexamethasone as an adjuvant to peripheral nerve block. Cochrane Database of …
TIGIT inhibitorsEtigilimabRilvegostomigTIGIT inhibitorPD1 inhibitorDargistotugBAT6021tiragolumab
…clinical trials of TIGIT inhibitors should be questioned. Seven TIGIT inhibitors (all Fc-enabled) did not recapitulate in clinical trials the pr…
sodium-glucose cotransporter 2 inhibitorsangiotensin converting enzyme inhibitorsKFREangiotensin II receptor blockers
…e to prevent the progression of chronic kidney disease, such as sodium-glucose cotransporter 2 inhibitors.Future research We recommend that our model should be validated…
nivolumabrelatlimab
…, nivolumab-(n=15), and nivolumab+relatlimab (n=14) followed by nivolumab+relatlimab in first-line advanced melanoma. Overall primary obj…
vidutolimodpembrolizumabvidutolimod-treatedZ-007
…r exceeding (>50X higher) pharmacodynamic responses reported to vidutolimod, yet with minimal inflammatory cytokine secretion. RNA-seq show…
PH1KadcylamPD-1Tras PH1Trastuzumab-DM1
…of MC38 rechallenge of completely regressed mice: Rationale for PH1 ADC synergy with anti PD-1. A. Completely regressed (CR) mice w…
elafibranorbezafibrate
…afibranor initiation. 2 (7.4%) patients continued OCA alongside elafibranor. 19 (70.4%) patients had trialled bezafibrate prior to elafibra…
remifentanil-PCA
…ession requiring mask ventilation or intubation associated with remifentanil-PCA usage. This positive safety record can be attributed to our wel…
tirzepatideorforglipronphentermine-topiramateCagriSemanaltrexone-bupropionSubcutaneous semaglutidemazdutideliraglutide
… with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particul…